Liposome News and Research

Latest Liposome News and Research

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

NeoPharm, Inc. today announced that it has submitted a Phase II protocol to the FDA for the study of liposome entrapped docetaxel (LE-DT), a novel, proprietary liposomal delivery system of docetaxel, the active ingredient of Taxotere®, for locally advanced or metastatic pancreatic cancer patients.

27 Oct 2009

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Celsion Corporation and Yakult Honsha Co., Ltd. announced today that the first patient has been enrolled and treated in Japan as part of Celsion’s global Phase III ThermoDox HEAT trial for the treatment of hepatocellular carcinoma (HCC), the most common form of primary liver cancer.

27 Oct 2009

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Millennium: The Takeda Oncology Company today announced the initiation of a Phase II clinical trial examining rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) with or without VELCADE® (bortezomib) for Injection for patients with a common type of lymphoma. The study will examine previously untreated patients with a genomically defined subtype of lymphoma called non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma.

22 Oct 2009

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Celsion Corporation announced today that it has completed a critical regulatory step in the countries of China and Japan to rapidly enroll patients in its global Phase III ThermoDox trial for the treatment of Hepatocellular Carcinoma (HCC), also known as primary liver cancer.

21 Oct 2009

Positive results from Transave's Phase II ARIKACE clinical trials

Transave Inc., today reported additional positive clinical trial results on its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation), an antibiotic that aims to treat chronic lung infections.

20 Oct 2009

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

Celsion Corporation announced today that it has received approval from the regulatory agencis in the Philippines and Malaysia for its Pivotal Phase III primary liver cancer Clinical Trial Application.

19 Oct 2009

China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer

Celsion Corporation announced today that it has received official approval from China’s State Food and Drug Administration (“SFDA”) for its Clinical Trial Application for ThermoDox that permits Celsion to include Chinese clinical trial sites in its Phase III ThermoDox HEAT trial for the treatment of primary liver cancer, also known as hepatocellular carcinoma (HCC).

15 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

YM BioSciences to acquire Cytopia

Cytopia Limited has today announced that Cytopia and Toronto-based YM BioSciences Inc. ("YM") have signed an exclusive and binding Implementation Agreement ("Agreement") in which it is proposed that YM will acquire all of the issued shares and options in Cytopia.

6 Oct 2009

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

YM BioSciences Inc. a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported operational and financial results for its fiscal year end, ended June 30, 2009.

25 Sep 2009

Research to improve the targeting of chemotherapeutic drugs to specific cells

Kenneth Longmuir, associate professor of physiology & biophysics, and Richard Robertson, professor of anatomy & neurobiology, used liposomes, small spheres (less-than 100 nanometer in diameter) of naturally-occurring lipid molecules, as "packages" for the cancer chemotherapeutic agent doxorubicin, and a small peptide molecule to "address" the package to the targeted tissue.

25 Sep 2009

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

Royal Philips Electronics (NYSE: PHG; AEX: PHI) and Celsion Corporation (NASDAQ: CLSN) today announced that their joint research program to evaluate ThermoDox® in combination with MR-HIFU (Magnetic Resonance guided High Intensity Focused Ultrasound) as a combination therapy to non-invasively treat difficult cancers has successfully completed the feasibility stage.

23 Sep 2009

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Merck Serono, a division of Merck KGaA, Darmstadt, Germany, today announced that Erbitux® (cetuximab) demonstrated a significant improvement in overall survival (OS) when added to standard 1st-line chemotherapy for metastatic colorectal cancer (mCRC) patients with KRAS wild-type tumors.

23 Sep 2009

Bio-Path Holdings to develop liposome tumor targeting technology

Bio-Path Holdings, Inc. (OTCBB: BPTH), a publicly traded biotechnology company with drug development operations in Houston, Texas, announced today the Company has executed an exclusive license with The University of Texas M. D. Anderson Cancer Center to develop liposome tumor targeting technology. Bio-Path is currently developing a neutral-lipid based liposome delivery technology for nucleic acid cancer drugs (including antisense and siRNA molecules).

23 Sep 2009

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Celsion Corporation (NASDAQ:CLSN) announced today the Data Safety Monitoring Board (“DSMB”) has reviewed the safety data from the first group of patients enrolled in its pivotal ThermoDox® Phase III clinical trial for primary liver cancer (“HEAT study”) and has recommended that Celsion continue to enroll patients in the trial.

21 Sep 2009

Millennium's sNDA for VELCADE granted priority review by the FDA

Millennium: The Takeda Oncology Company today announced that the U.S. Food and Drug Administration (FDA) has granted priority review to the Company’s supplemental new drug application (sNDA) for VELCADE. The sNDA contains long-term overall survival (OS) data from the landmark VISTA trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

19 Sep 2009

Nimotuzumab drug approved for Mexican distribution

YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM, AIM:YMBA), a life sciences product development company that identifies and advances a diverse portfolio of promising cancer-related products at various stages of development, today reported that nimotuzumab has been approved for marketing in Mexico.

17 Sep 2009

Celsion's DIGNITY clinical trial aired on Good Morning America

Celsion Corporation announced today the Company’s DIGNITY clinical trial evaluating the use of ThermoDox in combination with hyperthermia for the treatment of Recurrent Chest Wall (RCW) Breast Cancer was aired during commercial breaks on Good Morning America and CBS Sunday Morning this past weekend.

16 Sep 2009

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

Transave, Inc., today reported positive results from a Phase II clinical trial in non-cystic fibrosis (CF) bronchiectasis patients for its lead investigational drug, ARIKACE(TM) (liposomal amikacin for inhalation). The Phase II data indicated that ARIKACE, delivered once daily for 28 consecutive days, demonstrated superior clinical benefit compared to placebo as measured by patient and physician reported outcomes and reduction in Pseudomonas aeruginosa density.

14 Sep 2009

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Celsion Corporation (NASDAQ:CLSN) and the American Liver Foundation (ALF) announced today that they have formed a partnership to provide education to physicians and liver patients about the treatment options for hepatocellular carcinoma (commonly referred to as primary liver cancer) and Celsion’s on-going ThermoDox Phase III global HEAT clinical study.

14 Sep 2009

Liposome News and Research

Latest Liposome News and Research

NeoPharma submits a Phase II protocol to the FDA for its liposome entrapped docetaxel study

First Japanese patient treated in Celsion’s global Phase III ThermoDox HEAT trial

Millennium commences Vc-R-CHOP Phase II trial for diffuse large B-cell lymphoma

Celsion completes patient enrollment in its global Phase III ThermoDox trial

Positive results from Transave's Phase II ARIKACE clinical trials

Philippines and Malaysian regulatory agencies approve Celsion’s Phase III Thermodox trial

China's SFDA approves Celsion’s global Phase III ThermoDox HEAT trial for treating liver cancer

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

YM BioSciences to acquire Cytopia

US Treasury Department clears YM BioSciences' nimotuzumab clinical program extension

Research to improve the targeting of chemotherapeutic drugs to specific cells

The ThermoDox and MR-HIFU program shows great promise for treating life-threatening cancers

EGFR-targeted therapy improves survival rates in metastatic colorectal cancer patients

Bio-Path Holdings to develop liposome tumor targeting technology

Celsion recommended to continue patient enrollment in its ThermoDox Phase III liver cancer trial

Millennium's sNDA for VELCADE granted priority review by the FDA

Nimotuzumab drug approved for Mexican distribution

Celsion's DIGNITY clinical trial aired on Good Morning America

Positive results from Transave's Phase II clinical trial of ARIKACE in non-CF bronchiectasis patients

ALF, Celsion partner to educate physicians about primary liver cancer treatments

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production